Overview

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study for the Safety Run-In Cohort is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel in metastatic triple-negative breast cancer (mTNBC). The primary objective of this study for the Randomized Cohorts is to evaluate the efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel in solid tumors as determined by progression-free survival (PFS) by investigator assessment.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Albumin-Bound Paclitaxel
Magrolimab
Paclitaxel